Matinas BioPharma Inc

MTNB

Latest QuantConomy context for MTNB: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class

stock

Primary venue

AMEX

Recent signals

SEC filings

Asset profile

QuantConomy has a structured record for MTNB. More descriptive asset metadata will appear here when the platform record includes it.

Latest signal rows

Recent signals for MTNB

Scored rows are pulled from the same signal API used by the digests.

Signal	Direction	Score	Observed	Reason
fundamental operating income change	very bullish	76	Jul 11, 12:00 AM	MTNB (Q1 2026, operating income): grew 72.2% (-$6.96M → -$1.94M). [sequential period basis, very bullish signal]
fundamental eps change	very bullish	76	Jul 11, 12:00 AM	MTNB (Q1 2026, diluted eps): EPS grew 85.0% ($-2.00 → $-0.30). [sequential period basis, very bullish signal]
corporate event delisting	very bearish	85	Jun 26, 09:30 PM	MTNB filed 8-K: Delisting Notice, Other Events - 2 material events - [very strong very bearish signal]

FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.

Market	Exchange	Source	Asset record
MTNB	AMEX	fmp	Matinas BioPharma Holdings, Inc.
MTNB	AMEX	alpaca	Matinas BioPharma Holdings, Inc.
MTNB	NYSE MKT	alphavantage	Matinas Biopharma Holdings Inc

Buys, last 90d

Sells, last 90d

Rows

No recent Form 3, 4, or 5 insider transaction rows were returned for MTNB.

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.